Active ingredient in Ritalin, Concerta, etc. Over 40 years of experience provide a known efficacy and safety profile.
Approved as an antihistamine in the 1960s but not used due to drowsiness. Until now, not shown to have an impact on ADHD and growth.
The two ingredients are timed for optimal treatment of ADHD and maximization of daytime nutrition. Alternative combination regimens have been shown not to work.
Effective at multiple strengths allowing full treatment of ADHD symptoms for the individual patient
Easy to administer at home in the morning. This ensures that children can be fully treated during the school day.
Unlike cyproheptadine alone or in alternative delivery regimens, ATT-377 does not cause drowsiness.
Within the first week of treatment, patients have significantly better (p<.001) appetites than on methylphenidate alone. This includes a improvement on appetite at lunchtime.
At study completion, weight increased significantly more (p<.0001) with ATT-377 than in the control arm. This robust response was also seen when adjusted for age and gender using the CDC growth curves. 12 weeks is longer than a typical ADHD study period indicating a enduring effect of treatment.
Subgroup analysis shows that patients who had never taken therapy for ADHD, were protected by ATT-377 vs. those in the control group.
The combination pulsatile delivery of cyproheptadine during the daytime did not decrease the effectiveness of methylphenidate on ADHD.
Methylphenidate doses ranged from 18mg to 72mg in the clinical trial.